key: cord-0782638-gb07lgig authors: Tizabi, Yousef; Getachew, Bruk; Copeland, Robert L.; Aschner, Michael title: Nicotine and the nicotinic cholinergic system in COVID‐19 date: 2020-08-13 journal: FEBS J DOI: 10.1111/febs.15521 sha: 57b0524224c26de20c5587795e04ea3ad2a2b485 doc_id: 782638 cord_uid: gb07lgig There is an urgent need to address the devastating pandemic, COVID‐19, caused by SARS‐CoV‐2. The efforts to understand the details of this disease in hope of providing effective treatments is commendable. It is clear now that the virus can cause far more damage in patients with co‐morbid conditions ‐ particularly in those with respiratory, cardiovascular or immune‐compromised system ‐ than in patients without such co‐morbidities. Drug use can further exacerbate the condition. In this regard, the ill effects of smoking are amply documented, and no doubt can be a confounding factor in COVID‐19 progression. Although conflicting hypotheses on the potential role of nicotine in COVID‐19 pathology have recently been offered, we believe that nicotine itself, through its interaction with the nicotinic cholinergic system, as well as ACE2, may not only be of use in a variety of neuropsychiatric and neurodegenerative diseases, but may also be of potential use in COVID‐19. Thus, on one hand, while we strongly support smoking cessation as a means of harm reduction associated with COVID‐19, on the other hand, we support a potential therapeutic role for nicotine, nicotinic agonists or positive allosteric modulators of nicotinic cholinergic receptors in COVID‐19, owing to their varied effects including mood regulation, anti‐inflammatory as well as purported interference with SARS‐CoV‐2 entry and/or replication. The world-wide toll exacted by a single-stranded RNA virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leading to the corona virus disease of 2019 , is a wake-up call to better understand the role of viruses, infectious elements and to come up with an improved strategy for collective responses to pandemics. It is quite evident that COVID-19 pathologies discriminately involve patients with underlying diseases such as hypertension, cardiovascular and cerebrovascular diseases, diabetes, hepatitis B infections, chronic obstructive pulmonary disease, chronic kidney diseases, malignancy and immunodeficiency vs. those without such conditions. Expectedly, having two or more co-morbidities further escalates the risks of succumbing to COVID-19 [1, 2, 3] . COVID-19 could also be hitting hard some populations with substance use disorders (SUDs) owing to the fact that people who use tobacco or marijuana or those with opioid or methamphetamine use disorders may have compromised respiratory and pulmonary health [4] . Similarly, alcohol use disorder (AUD), by impairing the immune system and increasing susceptibility to respiratory illnesses could contribute to greater mortality risk when combined with COVID-19 [5] . There is, however, considerable controversy regarding the interaction of the plant alkaloid nicotine with COVID-19. nAChRs, target of nicotine, belong to ionotropic class of receptors, which act by directly regulating the opening of a cation channel in the neuronal membrane [6, 7, 8] . Various subtypes of these receptors with distinct anatomical, physiological, and pharmacological characteristics have been identified [6] . Although nAChRs are present at the neuromuscular junction, autonomic ganglia and the central nervous system, the subunit structures of these receptors are different from each other [9] . Considerable information on interaction between neuronal nicotinic receptors, consisting mainly of alph4-beta2 or homomeric alpha7 subunits and other neurotransmitter systems is now available. Moreover, specific responses of these receptors to nicotine and their involvement in cognitive functions have been investigated [10, 11] . Indeed, therapeutic potentials for selective nicotinic receptor This article is protected by copyright. All rights reserved agonists in various neuropsychiatric and neurodegenerative disorders have been suggested. These include Parkinson's disease and Alzheimer's disease, schizophrenia, depression, pain as well as smoking cessation [12, 13, 14, 15] . The potential role of nicotinic receptors in high-order cognitive processing has been recently reviewed [16] . It is also of relevance that acetylcholine (ACh), both centrally and peripherally acts not only through the nicotinic, but also the muscarinic receptors, which are G-protein-coupled receptors and act via the second messenger system. Our emphasis here is solely on the ionotropic nicotinic receptors that act directly on channel opening. It is now believed that there exists a cholinergic anti-inflammatory pathway that acts through nicotinic acetylcholine receptors [17, 18] . Thus, activation of these receptors (particularly α7 nAChR) can suppress production of pro-inflammatory cytokines as these receptors are abundantly expressed in variety of immune cells including B cells, T cells and macrophages [19] . Indeed, nicotine has been shown to inhibit pro-inflammatory cytokines such as tumor necrosis factorα (TNF-α), interleukin-1 (IL-1), IL-6 without affecting the anti-inflammatory cytokines such as IL-10 [20,21]. Interestingly, several animal models associated with elevated levels of pro-inflammatory cytokines such as sepsis, ischemia-reperfusion and pancreatitis show improvement by stimulation of the vagus nerve, which is believed to be mediated via activation of α7 nAChRs on macrophages [22] . Moreover, mice deficient in α7 nAChRs exhibit increased endotoxin-induced TNF-α production, which do not respond to electrical vagal stimulation [22] . Thus, it may be concluded that nicotinevia α7 nAChR stimulation -might lead to inhibition of cytokine storm associated with COVID-19 described further below. Importantly, nicotine use has been advocated in diseases associated with immune dysregulation (autoimmune diseases) or various inflammatory diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and inflammatory bowel diseases [23,24,25]. Substantial evidence indicates adverse effects of smoking on COVID-19 including predisposition to the virus infection, severity of progression and mortality [1, 26, 27, 28, 29] . However, there is a metaanalysis report that concludes that active smoking is not associated with severity of coronavirus This article is protected by copyright. All rights reserved disease [30] , although this contention has been challenged [26] . Still, some studies claim to have found a lower incidence of hospitalized COVID-19 patients among smokers [31,32]. However, the evidence accumulated up to now suggests that although smokers might be less hospitalized, their health risk increases as soon as they are hospitalized [33] . Thus, it seems prudent to indicate that smoking is a risk factor for COVID-19 given the overwhelming epidemiological evidence cited above. However, the relationship of the stimulant in cigarettes, nicotine, with COVID-19 is far from clear. Thus, some investigators argue that because of known nicotinic receptor interactions with angiotensin-converting enzyme 2 (ACE2), a channel for SARS-CoV-2 entry into cells, nicotine exposure can increase the risk for COVID-19 damage, including neuro-infection [34]. Moreover, it was reported that exposure to nicotine causes epithelial cells to increase ACE2 levels, whereas gene silencing of α7 nAChR appears to significantly dampen this response [35], leading to the suggestion that perhaps α7 nAChR-selective antagonists, by altering ACE2 expression, may prevent SARS-CoV-2 entry into the airway epithelium [36]. These contentions, however, stand in stark contrast with potential beneficial effects of nicotine or nicotinic agonists in a variety of diseases [13, 37] , including COVID-19 [18,19,38]. Part of these discrepancies might stem from the way of interpreting studies; for example, some of the conclusions on the impact of smoking on COVID-19 are inferred, rather than directly analyzed [1, 31] . Another possible reason for the discrepancies might lie in the attempt to predict the final outcome of a drug based on its presumptive mode of action [38, 39] . Interaction of nicotine with ACE2 appears to be far more complicated to allow a definite prediction of the entry of the SARS-CoV-2 into the epithelium. This is due to the fact that not only our full understanding of the role of ACE2 in general, and in COVID-19 in particular, is incomplete, but also our knowledge of interaction between nicotine and ACE2 is far from clear [38,39,40,41]. Thus, although it is believed that SARS-CoV-2 uses ACE2 as a receptor for cell entry, involvement of other receptors cannot be totally ruled out [38, 41, 42, 43, 44] . Moreover, SARS-CoV-2 has been reported to either down-regulate [45, 46, 47] or up-regulate ACE2 [28, 36, 48] . In this regard, it is important to note that ACE2 polymorphism, which could influence both the susceptibility of people to SARS-CoV-2 infection and the outcome of the COVID-19 was recently described in human populations [40, 45] . Importantly, it has been Accepted Article hypothesized that increased ACE2 levels may actually be beneficial rather than harmful, particularly in patients with lung injury as it has been shown to have potent vasodilatory, anti-inflammatory and antioxidant properties [49, 50, 51] . Interestingly, children and younger adults, who have milder COVID-19 symptoms, have higher ACE2 levels compared to older people [52] . On one hand, it is proposed that smoking or nicotine may upregulate the detrimental angiotensin- The postulated mechanism for the efficacy of nicotine in infectious diseases in general, and in COVID-19 in particular, includes restoring and re-activating the cholinergic anti-inflammatory pathway that can suppress the cytokine storm, also referred to as macrophage activation syndrome This article is protected by copyright. All rights reserved [31, 38, 58] . Animal studies also show that nicotine, by reducing leukocyte infiltration and proinflammatory mediators in bronchoalveolar lavage fluid, has protective effects against lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) [65, 66] . Thus, as recently advocated by González-Rubio and colleagues, use of nicotine or nicotinic agonists may also be effective in ameliorating cytokine storm by inhibiting several cytokines simultaneously [18]. It is of interest to note that SARS-CoV-2 may enter the central nervous system (CNS) through the blood stream, via the olfactory nerve across the cribriform plate, by disrupting the blood brain barrier (BBB) or infecting the peripheral nerves [43, 67, 68, 69] , where it may cause ACE2 down-regulation and a local inflammatory response referred to as neuroinvasion, a common feature of coronaviruses [70] . Indeed, COVID-19 has been shown to be associated with CNS and neurological effects (e.g. dizziness, headache, confusion, agitation, anxiety, depression, strokes, seizures and loss of smell and taste) [71, 72] . A recent report indicates that neurological complications may be manifested in more than half of hospitalized COVID-19 patients [73] . The established anti-inflammatory effects of nicotine, together with its capability to improve olfactory impairment in a mouse model of Parkinson's disease [74] , provide further credence to its potential usefulness in COVID-19, as loss of smell is also a common symptom of COVID-19 [75] . Moreover, nicotine might counter some of the neurological effects of COVID-19, not only because of its antiinflammatory, but also because of its neuroprotectant and mood improvement properties [13, 14, 15] . Indeed, it has been proposed that COVID-19 may be a disease of the cholinergic nicotinic system [76] . Hence, nicotine administration could be added on top of antiviral or other therapeutic options for COVID-19. This application is very feasible as various pharmaceutical nicotine products such as nicotine patch, gum, nasal spray, inhaler, etc. are already available and FDA-approved for smoking cessation. Additionally, while some cytokine inhibitors are associated with elevated risk of opportunistic infections [77] , no such effect has been attributed to pure nicotine [78] . In this regard, it is noteworthy that the mode of nicotine administration has to be carefully considered as the pharmacokinetic and pharmacodynamic of different nicotinic preparation can be significantly This article is protected by copyright. All rights reserved different [79] . Recently, it has also been proposed that positive allosteric modulators of the α7 nAChRs may be used to boost nicotine's effects in countering excessive inflammation caused by SARS-CoV-2 [80] . Interestingly, ivermectin, a positive allosteric modulator of a7nAChR [81] , has been shown to inhibit the replication of SARS-CoV-2 in cells in vitro [82] . Hence it may be suggested that a combination of nicotine and ivermectin might be a reasonable pharmacotherapy in COVID-19. In the same vein, it should be noted that cotinine, a metabolite of nicotine, but without its addictive properties, has been shown to have similar anti-inflammatory effects as nicotine and hence cotinine or selective nAChR agonists or even varenicline, a partial alpha4-beta2 agonist used for smoking cessation may be potential substitutes for nicotine [83, 84] . Finally, another prominent feature of COVID-19 is coagulopathy that results in thromboembolic complications which are associated with higher mortality rate [85, 86] . Interestingly, platelets express functional α7 nAChRs , deficiency of which may increase platelet activity and increase the chance of clot formation [87] . Since acetylcholine may act as an endogenous inhibitor of platelet -cigarette smoking toxicity is exacerbated by SARS- Comorbidity and its impacts on 1590 patients with COVID-19 in China: a nationwide analysis Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity Cognitive Effects of Nicotine: Recent Progress Womelsdorf T. Dissociation of nicotinic α7 and α4/β2 subreceptor agonists for enhancing learning and attentional filtering in nonhuman primates New insights on focus on α7 nAChRs Novel targets for parkinsonism-depression comorbidity Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression Severity of negative mood and anxiety symptoms occurring during acute abstinence from tobacco: A systematic review and meta-analysis Do nicotinic receptors modulate high-order cognitive processing The inflammatory reflex Accepted Article This article is protected by copyright. All rights reserved CoV-2 spike glycoprotein and neuronal nicotinic acetylcholine receptors Renin-angiotensin system at the heart of COVID-19 pandemic Covid-19: the renin-angiotensin system imbalance hypothesis The pivotal link between ACE2 deficiency and SARS-CoV-2 infection The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV Drugs, COVID-19' working group of the French Society of Pharmacology, Therapeutics. Renin-angiotensin-aldosterone system and COVID-19 infection Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon Renin-angiotensin system blockers Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 COVID-19 infection and the predictive ACE2 soluble levels: the favourable protection of children and women UK COVID-19: consider cytokine storm syndromes and immunosuppression Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Protective effect of nicotine on lipopolysaccharideinduced acute lung injury in mice Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury Neurology in the time of covid-19 Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms Sever acute respiratory syndrome coronavirus-2 may be an underappreciated pathogen of the central nervous system Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses Accepted Article This article is protected by copyright. All rights reserved Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China Spectrum of neuropsychiatric manifestations in COVID-19 Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry Nicotine improved the olfactory impairment in MPTP-induced mouse model of Parkinson's disease Smell dysfunction: a biomarker for COVID-19 (2020) Nicotine and SARS-CoV COVID-19 may be a disease of the nicotinic cholinergic system Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Wound Healing and Infection in Surgery: The Pathophysiological Impact of Smoking, Smoking Cessation, and Nicotine Replacement Therapy: A Systematic Review Nicotinic receptor intervention in Parkinson's disease: future directions A Contribution to the hypothesis of nicotine challenge as therapeutics option for COVOID-19 patients Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Neuroinflammation: a therapeutic target of cotinine for the treatment of psychiatric disorders? Discovery and development of varenicline for smoking cessation Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Hematopoietic α7 nicotinic acetylcholine receptor deficiency increases inflammation and platelet activation status but does not aggravate atherosclerosis This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved